Thyromimetics improve disease endpoints and modulate potential target engagement biomarkers in rodent models of ALD and MS (P3-4.011) — Michaelanne Woerner (2022) | RDL Network
Thyromimetics improve disease endpoints and modulate potential target engagement biomarkers in rodent models of ALD and MS (P3-4.011)
Article 2022 en
Authors
MW
Michaelanne Woerner
JV
Jeffrey A. Vivian
AA
Aryan Alavi
Abstract
1 min read
To investigate preclinical efficacy and identify potential biomarkers of CNS-delivered thyromimetics in disease models of remyelination relevant to neurodegeneration.
Patrizia Fanara, Po‐yin Anne Wong, Kristofor H. Husted, Shanshan Liu, Victoria M. Liu, Lori A. Kohlstaedt, Timothy Riiff, Joan C. Protasio, Drina Boban, Salena Killion, Maudi Killian, Lorrie Epling, Elisabeth Sinclair, Julia Peterson, Richard W. Price, Deborah E. Cabin, Robert L. Nussbaum, Jörg Brühmann, Roland Brandt, Chadwick W. Christine, Michael J. Aminoff, Marc Hellerstein
Honghuang Lin, Jayandra J. Himali, Claudia L. Satizábal, Alexa S. Beiser, Daniel Levy, Emelia Benjamin, Mitzi M. Gonzales, Saptaparni Ghosh, Ramachandran S. Vasan, Sudha Seshadri, Emer R. McGrath
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.